Acute Gout Flare Market Dynamics Indicate Upward Trajectory Through 2034, Reports Delveinsight Olatec Therapeutics, Dyve Biosciences, Changchun Genescience Pharma, Regeneron Pharma, Novartis

(MENAFN- GetNews)

The Key Acute Gout Flare Companies in the market include - Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem, Novartis, Organon and Co, Revive Therapeutics, Ltd., and others.

DelveInsight's “Acute Gout Flare Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Acute Gout Flare, historical and forecasted epidemiology as well as the Acute Gout Flare market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Acute Gout Flare market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Gout Flare Market Forecast

Some of the key facts of the Acute Gout Flare Market Report:

• The Acute Gout Flare market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In September 2025, Atom Therapeutics , a clinical-stage biotechnology company focused on developing advanced therapies for inflammatory and metabolic diseases, announced the enrollment of the first patient in a multi-country Phase 2 trial of ABP-745, a novel anti-inflammatory drug for treating painful acute gout flares. The study, conducted across sites in the US, China, and Australia, aims to enroll over 200 patients in a randomized, double-blind trial to assess the safety, efficacy, and pharmacodynamics of ABP-745 in alleviating pain and swelling during acute gout episodes. The ABP-745 dosing regimen will be compared with placebo and colchicine, the standard treatment for gout flares.

• In May 2025, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced the launch of a Phase 4 clinical trial at Massachusetts General Hospital to evaluate the safety and efficacy of two dosage levels (40 USP units and 80 USP units) of Purified Cortrophin Gel (repository corticotropin injection USP) for treating acute gout flares. Cortrophin Gel is intended for short-term use as an adjunct therapy during acute episodes or exacerbations of acute gouty arthritis and is contraindicated for intravenous administration. Additional important safety information is provided below.

• In February 2024, Dapansutrile (lab code: OLT1177®) is an experimental small molecule that targets and inhibits NLRP3 (nucleotide-binding and oligomerization domain [NOD]‐, leucine-rich repeat-, pyrin domain-containing 3), a key sensor molecule involved in the formation of the NLRP3 inflammasome. Inflammasomes are multiprotein complexes that detect danger signals inside cells and trigger a strong inflammatory response by generating bioactive IL-1β and IL-18 through caspase-1 activation. Dapansutrile has been shown to block the formation of the NLRP3 inflammasome, preventing the production of IL-1β and IL-18. It has been well tolerated and demonstrated to improve clinical outcomes in patients experiencing acute gout flare and heart failure.

• The overall occurrence of gout affects 1–4% of the general population. There is a higher susceptibility to gout in men compared to women. In Western countries, the prevalence is approximately 3–6% in men and 1–2% in women.

• Gout results in around 7 million outpatient visits in the United States each year, incurring a cost of almost USD 1 billion.

• Key Acute Gout Flare Companies: Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem, Novartis, Organon and Co, Revive Therapeutics, Ltd., and others

• Key Acute Gout Flare Therapies: Dapansutrile, DYV700, Genakumab for injection, Rilonacept, ACZ885, Tigulixostat, Canakinumab, MK0663, Bucillamine, and others

• Based on the analysis, the annual incidence of gout in the UK is 2.68 cases per 1,000 individuals.

• Gout is more common in men than women. In Western countries, it affects 3–6% of men and 1–2% of women, with prevalence in some regions potentially rising to as high as 10%.

• Recent reports on the prevalence and incidence of gout show significant variation depending on the population studied and the methods used. Prevalence ranges from less than 1% to 6.8%, while incidence falls between 0.58 and 2.89 per 1,000 person-years. Gout is more common in men than women and increases with age. Both the prevalence and incidence of gout appear to be rising worldwide.

• Gout impacts around 9.2 million individuals in the US, representing about 3.9% of the adult population. It is more prevalent in men and among older adults.

• The analysis indicates that the standardized prevalence of gout in Germany was 1.63%, affecting roughly 1.325 million individuals. The standardized incidence rate was 0.45%. The male-to-female ratio was 3.2 for prevalence and 2.7 for incidence. The average age at diagnosis is estimated to be 66 years.

• The Acute Gout Flare epidemiology based on gender analyzed that Gout is three times more prevalent in males than females

• The Acute Gout Flare market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Gout Flare pipeline products will significantly revolutionize the Acute Gout Flare market dynamics.

Acute Gout Flare Overview

An acute gout flare refers to a sudden and intense episode of pain, swelling, redness, and tenderness in a joint caused by the inflammatory response to the crystallization of uric acid in the joint. Gout is a type of arthritis characterized by elevated levels of uric acid in the blood, leading to the formation of urate crystals in the joints.

Get a Free sample for the Acute Gout Flare Market Forecast, Size & Share Analysis Report:

Acute Gout Flare Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Gout Flare Epidemiology Segmentation:

The Acute Gout Flare market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Acute Gout Flare

• Prevalent Cases of Acute Gout Flare by severity

• Gender-specific Prevalence of Acute Gout Flare

• Diagnosed Cases of Episodic and Chronic Acute Gout Flare

Download the report to understand which factors are driving Acute Gout Flare epidemiology trends @ Acute Gout Flare Epidemiology Forecast

Acute Gout Flare Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Gout Flare market or expected to get launched during the study period. The analysis covers Acute Gout Flare market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Gout Flare Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Gout Flare Therapies and Key Companies

• Dapansutrile: Olatec Therapeutics

• DYV700: Dyve Biosciences

• Genakumab for injection: Changchun GeneScience Pharma

• Rilonacept: Regeneron Pharmaceuticals

• ACZ885: Novartis

• Tigulixostat: LG Chem

• Canakinumab: Novartis

• MK0663: Organon and Co

• Bucillamine: Revive Therapeutics, Ltd.

Discover more about therapies set to grab major Acute Gout Flare market share @ Acute Gout Flare Treatment Landscape

Scope of the Acute Gout Flare Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Acute Gout Flare Companies: Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem, Novartis, Organon and Co, Revive Therapeutics, Ltd., and others

• Key Acute Gout Flare Therapies: Dapansutrile, DYV700, Genakumab for injection, Rilonacept, ACZ885, Tigulixostat, Canakinumab, MK0663, Bucillamine, and others

• Acute Gout Flare Therapeutic Assessment: Acute Gout Flare current marketed and Acute Gout Flare emerging therapies

• Acute Gout Flare Market Dynamics: Acute Gout Flare market drivers and Acute Gout Flare market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

• Acute Gout Flare Unmet Needs, KOL's views, Analyst's views, Acute Gout Flare Market Access and Reimbursement

To know more about Acute Gout Flare companies working in the treatment market, visit @ Acute Gout Flare Clinical Trials and Therapeutic Assessment

Table of Contents

1. Acute Gout Flare Market Report Introduction

2. Executive Summary for Acute Gout Flare

3. SWOT analysis of Acute Gout Flare

4. Acute Gout Flare Patient Share (%) Overview at a Glance

5. Acute Gout Flare Market Overview at a Glance

6. Acute Gout Flare Disease Background and Overview

7. Acute Gout Flare Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Gout Flare

9. Acute Gout Flare Current Treatment and Medical Practices

10. Acute Gout Flare Unmet Needs

11. Acute Gout Flare Emerging Therapies

12. Acute Gout Flare Market Outlook

13. Country-Wise Acute Gout Flare Market Analysis (2020–2034)

14. Acute Gout Flare Market Access and Reimbursement of Therapies

15. Acute Gout Flare Market Drivers

16. Acute Gout Flare Market Barriers

17. Acute Gout Flare Appendix

18. Acute Gout Flare Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

MENAFN30092025003238003268ID1110132433